The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Blood Pressure Disorders Drug Market Research Report 2025

Global Blood Pressure Disorders Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1720631

No of Pages : 102

Ask Your Query
Synopsis
Blood pressure disorder drug development technology and related units
The global Blood Pressure Disorders Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Blood Pressure Disorders Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Pressure Disorders Drug.
Report Scope
The Blood Pressure Disorders Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Blood Pressure Disorders Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Pressure Disorders Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
A1M Pharma AB
Acceleron Pharma Inc
Ache Laboratorios Farmaceuticos SA
Actelion Pharmaceuticals Ltd
Aerogen Ltd
Anavex Life Sciences Corp
AnGes Inc
Arena Pharmaceuticals Inc
Ascendia Pharmaceuticals LLC
Ascendis Pharma A/S
AVEO Pharmaceuticals Inc
Bayer AG
Bial - Portela & Ca SA
Bioblue Technologies Inc
Biogen Inc
Biolab Farmaceutica Ltda
BioRestorative Therapies Inc
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
CJ HealthCare Corp
Complexa Inc
Corion Biotech Srl
Segment by Type
Diuretics
Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARBs)
Others
Segment by Application
Hypertension
Hypotension
Pulmonary Hypertension
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Pressure Disorders Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Pressure Disorders Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Diuretics
1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.4 Angiotensin Receptor Blockers (ARBs)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Blood Pressure Disorders Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hypertension
1.3.3 Hypotension
1.3.4 Pulmonary Hypertension
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Pressure Disorders Drug Market Perspective (2019-2030)
2.2 Blood Pressure Disorders Drug Growth Trends by Region
2.2.1 Global Blood Pressure Disorders Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Blood Pressure Disorders Drug Historic Market Size by Region (2019-2024)
2.2.3 Blood Pressure Disorders Drug Forecasted Market Size by Region (2025-2030)
2.3 Blood Pressure Disorders Drug Market Dynamics
2.3.1 Blood Pressure Disorders Drug Industry Trends
2.3.2 Blood Pressure Disorders Drug Market Drivers
2.3.3 Blood Pressure Disorders Drug Market Challenges
2.3.4 Blood Pressure Disorders Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Pressure Disorders Drug Players by Revenue
3.1.1 Global Top Blood Pressure Disorders Drug Players by Revenue (2019-2024)
3.1.2 Global Blood Pressure Disorders Drug Revenue Market Share by Players (2019-2024)
3.2 Global Blood Pressure Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Blood Pressure Disorders Drug Revenue
3.4 Global Blood Pressure Disorders Drug Market Concentration Ratio
3.4.1 Global Blood Pressure Disorders Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Pressure Disorders Drug Revenue in 2023
3.5 Blood Pressure Disorders Drug Key Players Head office and Area Served
3.6 Key Players Blood Pressure Disorders Drug Product Solution and Service
3.7 Date of Enter into Blood Pressure Disorders Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Pressure Disorders Drug Breakdown Data by Type
4.1 Global Blood Pressure Disorders Drug Historic Market Size by Type (2019-2024)
4.2 Global Blood Pressure Disorders Drug Forecasted Market Size by Type (2025-2030)
5 Blood Pressure Disorders Drug Breakdown Data by Application
5.1 Global Blood Pressure Disorders Drug Historic Market Size by Application (2019-2024)
5.2 Global Blood Pressure Disorders Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Blood Pressure Disorders Drug Market Size (2019-2030)
6.2 North America Blood Pressure Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Blood Pressure Disorders Drug Market Size by Country (2019-2024)
6.4 North America Blood Pressure Disorders Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Pressure Disorders Drug Market Size (2019-2030)
7.2 Europe Blood Pressure Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Blood Pressure Disorders Drug Market Size by Country (2019-2024)
7.4 Europe Blood Pressure Disorders Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Pressure Disorders Drug Market Size (2019-2030)
8.2 Asia-Pacific Blood Pressure Disorders Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Blood Pressure Disorders Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Blood Pressure Disorders Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Pressure Disorders Drug Market Size (2019-2030)
9.2 Latin America Blood Pressure Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Blood Pressure Disorders Drug Market Size by Country (2019-2024)
9.4 Latin America Blood Pressure Disorders Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Pressure Disorders Drug Market Size (2019-2030)
10.2 Middle East & Africa Blood Pressure Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Blood Pressure Disorders Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Blood Pressure Disorders Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 A1M Pharma AB
11.1.1 A1M Pharma AB Company Detail
11.1.2 A1M Pharma AB Business Overview
11.1.3 A1M Pharma AB Blood Pressure Disorders Drug Introduction
11.1.4 A1M Pharma AB Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.1.5 A1M Pharma AB Recent Development
11.2 Acceleron Pharma Inc
11.2.1 Acceleron Pharma Inc Company Detail
11.2.2 Acceleron Pharma Inc Business Overview
11.2.3 Acceleron Pharma Inc Blood Pressure Disorders Drug Introduction
11.2.4 Acceleron Pharma Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.2.5 Acceleron Pharma Inc Recent Development
11.3 Ache Laboratorios Farmaceuticos SA
11.3.1 Ache Laboratorios Farmaceuticos SA Company Detail
11.3.2 Ache Laboratorios Farmaceuticos SA Business Overview
11.3.3 Ache Laboratorios Farmaceuticos SA Blood Pressure Disorders Drug Introduction
11.3.4 Ache Laboratorios Farmaceuticos SA Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.3.5 Ache Laboratorios Farmaceuticos SA Recent Development
11.4 Actelion Pharmaceuticals Ltd
11.4.1 Actelion Pharmaceuticals Ltd Company Detail
11.4.2 Actelion Pharmaceuticals Ltd Business Overview
11.4.3 Actelion Pharmaceuticals Ltd Blood Pressure Disorders Drug Introduction
11.4.4 Actelion Pharmaceuticals Ltd Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.4.5 Actelion Pharmaceuticals Ltd Recent Development
11.5 Aerogen Ltd
11.5.1 Aerogen Ltd Company Detail
11.5.2 Aerogen Ltd Business Overview
11.5.3 Aerogen Ltd Blood Pressure Disorders Drug Introduction
11.5.4 Aerogen Ltd Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.5.5 Aerogen Ltd Recent Development
11.6 Anavex Life Sciences Corp
11.6.1 Anavex Life Sciences Corp Company Detail
11.6.2 Anavex Life Sciences Corp Business Overview
11.6.3 Anavex Life Sciences Corp Blood Pressure Disorders Drug Introduction
11.6.4 Anavex Life Sciences Corp Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.6.5 Anavex Life Sciences Corp Recent Development
11.7 AnGes Inc
11.7.1 AnGes Inc Company Detail
11.7.2 AnGes Inc Business Overview
11.7.3 AnGes Inc Blood Pressure Disorders Drug Introduction
11.7.4 AnGes Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.7.5 AnGes Inc Recent Development
11.8 Arena Pharmaceuticals Inc
11.8.1 Arena Pharmaceuticals Inc Company Detail
11.8.2 Arena Pharmaceuticals Inc Business Overview
11.8.3 Arena Pharmaceuticals Inc Blood Pressure Disorders Drug Introduction
11.8.4 Arena Pharmaceuticals Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.8.5 Arena Pharmaceuticals Inc Recent Development
11.9 Ascendia Pharmaceuticals LLC
11.9.1 Ascendia Pharmaceuticals LLC Company Detail
11.9.2 Ascendia Pharmaceuticals LLC Business Overview
11.9.3 Ascendia Pharmaceuticals LLC Blood Pressure Disorders Drug Introduction
11.9.4 Ascendia Pharmaceuticals LLC Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.9.5 Ascendia Pharmaceuticals LLC Recent Development
11.10 Ascendis Pharma A/S
11.10.1 Ascendis Pharma A/S Company Detail
11.10.2 Ascendis Pharma A/S Business Overview
11.10.3 Ascendis Pharma A/S Blood Pressure Disorders Drug Introduction
11.10.4 Ascendis Pharma A/S Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.10.5 Ascendis Pharma A/S Recent Development
11.11 AVEO Pharmaceuticals Inc
11.11.1 AVEO Pharmaceuticals Inc Company Detail
11.11.2 AVEO Pharmaceuticals Inc Business Overview
11.11.3 AVEO Pharmaceuticals Inc Blood Pressure Disorders Drug Introduction
11.11.4 AVEO Pharmaceuticals Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.11.5 AVEO Pharmaceuticals Inc Recent Development
11.12 Bayer AG
11.12.1 Bayer AG Company Detail
11.12.2 Bayer AG Business Overview
11.12.3 Bayer AG Blood Pressure Disorders Drug Introduction
11.12.4 Bayer AG Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.12.5 Bayer AG Recent Development
11.13 Bial - Portela & Ca SA
11.13.1 Bial - Portela & Ca SA Company Detail
11.13.2 Bial - Portela & Ca SA Business Overview
11.13.3 Bial - Portela & Ca SA Blood Pressure Disorders Drug Introduction
11.13.4 Bial - Portela & Ca SA Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.13.5 Bial - Portela & Ca SA Recent Development
11.14 Bioblue Technologies Inc
11.14.1 Bioblue Technologies Inc Company Detail
11.14.2 Bioblue Technologies Inc Business Overview
11.14.3 Bioblue Technologies Inc Blood Pressure Disorders Drug Introduction
11.14.4 Bioblue Technologies Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.14.5 Bioblue Technologies Inc Recent Development
11.15 Biogen Inc
11.15.1 Biogen Inc Company Detail
11.15.2 Biogen Inc Business Overview
11.15.3 Biogen Inc Blood Pressure Disorders Drug Introduction
11.15.4 Biogen Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.15.5 Biogen Inc Recent Development
11.16 Biolab Farmaceutica Ltda
11.16.1 Biolab Farmaceutica Ltda Company Detail
11.16.2 Biolab Farmaceutica Ltda Business Overview
11.16.3 Biolab Farmaceutica Ltda Blood Pressure Disorders Drug Introduction
11.16.4 Biolab Farmaceutica Ltda Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.16.5 Biolab Farmaceutica Ltda Recent Development
11.17 BioRestorative Therapies Inc
11.17.1 BioRestorative Therapies Inc Company Detail
11.17.2 BioRestorative Therapies Inc Business Overview
11.17.3 BioRestorative Therapies Inc Blood Pressure Disorders Drug Introduction
11.17.4 BioRestorative Therapies Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.17.5 BioRestorative Therapies Inc Recent Development
11.18 Boryung Pharmaceutical Co Ltd
11.18.1 Boryung Pharmaceutical Co Ltd Company Detail
11.18.2 Boryung Pharmaceutical Co Ltd Business Overview
11.18.3 Boryung Pharmaceutical Co Ltd Blood Pressure Disorders Drug Introduction
11.18.4 Boryung Pharmaceutical Co Ltd Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.18.5 Boryung Pharmaceutical Co Ltd Recent Development
11.19 Bristol-Myers Squibb Co
11.19.1 Bristol-Myers Squibb Co Company Detail
11.19.2 Bristol-Myers Squibb Co Business Overview
11.19.3 Bristol-Myers Squibb Co Blood Pressure Disorders Drug Introduction
11.19.4 Bristol-Myers Squibb Co Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.19.5 Bristol-Myers Squibb Co Recent Development
11.20 Camurus AB
11.20.1 Camurus AB Company Detail
11.20.2 Camurus AB Business Overview
11.20.3 Camurus AB Blood Pressure Disorders Drug Introduction
11.20.4 Camurus AB Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.20.5 Camurus AB Recent Development
11.21 Capricor Therapeutics Inc
11.21.1 Capricor Therapeutics Inc Company Detail
11.21.2 Capricor Therapeutics Inc Business Overview
11.21.3 Capricor Therapeutics Inc Blood Pressure Disorders Drug Introduction
11.21.4 Capricor Therapeutics Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.21.5 Capricor Therapeutics Inc Recent Development
11.22 Celsion Corp
11.22.1 Celsion Corp Company Detail
11.22.2 Celsion Corp Business Overview
11.22.3 Celsion Corp Blood Pressure Disorders Drug Introduction
11.22.4 Celsion Corp Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.22.5 Celsion Corp Recent Development
11.23 Celtaxsys Inc
11.23.1 Celtaxsys Inc Company Detail
11.23.2 Celtaxsys Inc Business Overview
11.23.3 Celtaxsys Inc Blood Pressure Disorders Drug Introduction
11.23.4 Celtaxsys Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.23.5 Celtaxsys Inc Recent Development
11.24 Chiesi Farmaceutici SpA
11.24.1 Chiesi Farmaceutici SpA Company Detail
11.24.2 Chiesi Farmaceutici SpA Business Overview
11.24.3 Chiesi Farmaceutici SpA Blood Pressure Disorders Drug Introduction
11.24.4 Chiesi Farmaceutici SpA Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.24.5 Chiesi Farmaceutici SpA Recent Development
11.25 Chong Kun Dang Pharmaceutical Corp
11.25.1 Chong Kun Dang Pharmaceutical Corp Company Detail
11.25.2 Chong Kun Dang Pharmaceutical Corp Business Overview
11.25.3 Chong Kun Dang Pharmaceutical Corp Blood Pressure Disorders Drug Introduction
11.25.4 Chong Kun Dang Pharmaceutical Corp Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.25.5 Chong Kun Dang Pharmaceutical Corp Recent Development
11.26 Chugai Pharmaceutical Co Ltd
11.26.1 Chugai Pharmaceutical Co Ltd Company Detail
11.26.2 Chugai Pharmaceutical Co Ltd Business Overview
11.26.3 Chugai Pharmaceutical Co Ltd Blood Pressure Disorders Drug Introduction
11.26.4 Chugai Pharmaceutical Co Ltd Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.26.5 Chugai Pharmaceutical Co Ltd Recent Development
11.27 CJ HealthCare Corp
11.27.1 CJ HealthCare Corp Company Detail
11.27.2 CJ HealthCare Corp Business Overview
11.27.3 CJ HealthCare Corp Blood Pressure Disorders Drug Introduction
11.27.4 CJ HealthCare Corp Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.27.5 CJ HealthCare Corp Recent Development
11.28 Complexa Inc
11.28.1 Complexa Inc Company Detail
11.28.2 Complexa Inc Business Overview
11.28.3 Complexa Inc Blood Pressure Disorders Drug Introduction
11.28.4 Complexa Inc Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.28.5 Complexa Inc Recent Development
11.29 Corion Biotech Srl
11.29.1 Corion Biotech Srl Company Detail
11.29.2 Corion Biotech Srl Business Overview
11.29.3 Corion Biotech Srl Blood Pressure Disorders Drug Introduction
11.29.4 Corion Biotech Srl Revenue in Blood Pressure Disorders Drug Business (2019-2024)
11.29.5 Corion Biotech Srl Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock